Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
It might. It might not. But thanks for your helpful contribution.
In other news "Xeros Technology Group plc announces the supply of 32 near-waterless washing machines to Encom Trading LLC, a wholly owned subsidiary of Electro RAK, a leading UAE-based infrastructure services company and the appointed partner in the UAE to Hydrofinity, Xeros' cleaning technologies brand.Electro RAK intends to install machines in premium hotels in the UAE. The first shipment will be made to Dubai during September."
Good news after the recent Cape Town order. These may be fairly small numbers but they show people are looking for solutions in the most water-stressed parts of the world. The more examples we can point to, the greater the likelihood of those numbers starting to grow significantly.
If I read it all correctly, the Hardman report suggested Dermapure sales growth of 37%, we got 73%. They said 50% growth at GBMV, we got 70%. EBITDA loss would increase to 4.9m, it shrank to £3.5m. Overall sales growth predicted at 33%, turned out to be 61%. So it seems we did indeed do significantly better than that report suggested. Not sure whether the market expected that - currently up around 6 per cent - nice, but not spectacular. Let's hope it's the start of a steady climb.
No activity here for five months, but if anyone is looking for further info it's worth looking at the article in the Sunday Times this Sunday, 26 August. https://www.thetimes.co.uk/article/has-the-world-of-biotech-investing-become-just-a-little-too-cosy-kg79qgprm - It's a generally sceptical piece that reflects on our reliance on Oxford Nanopore and the difficult stage that business is at as it looks at a Hong Kong listing. Also there's plenty of discussion over the investor base and the role of Woodford and Invesco. I think the case remains for a punt here - maybe not a big one, but a punt nonetheless and now is as good a time as any with the sp low and push coming to shove for our biggest asset.
Welcome news but we've always been confident that we were better than vancomycin. The issue has been whether big pharma was willing to take on such products. I can't see a sustained rise much above 50p just yet until science and route to market are clearer. Also, I know it's pointless, but wouldn't it have been lovely to see this happening if we were still in the game for DMD?
If the figures are better than Hardman suggest, then it seems to suggest a game of double bluff on the market by TRX and surely the IIs are cute to that. Whatever, I hope Nomlungu is right - the science and the business strategy here seem convincing to me and I'm reasonably confident that will, erm, trump the problems cited.
So it seems that, effectively, we've got the results today not next month. I don't see there's reason to doubt Hardman's figures and their "good progress, but still two/three years until any profits" verdict probably explains the little dip this week. I'm not saying this is a " tuck under the mattress and forget about share" - I still have a feeling there could be events over the coming months that make it worth checking in regularly - but any growth in sp is likely to be pretty slow I'd guess. A very good entry price though for any patient investors.
Well this is interesting. Our nice big Asian contract gets cancelled/delayed because of domestic procurement rules and this operates retrospectively, so deliverables already supplied are notionally returned to us while things are sorted out and our accounts for 2017-18 take a hit. But the company seems relaxed about it all and confident that the contract will be recommissioned when the paperwork is done. If they are right, this is a terrific buying opportunity - currently 16 per cent down. I suppose we could see another fall - maybe bigger - when the accounts appear showing the hit. Over the years there's always been jam tomorrow complaints about SRT and this might seem to be another case of that, but I am tempted...How do others see it?
This share has fallen for a long time now so the turn around will I reckon take a lot longer than this. If the good news keeps coming we'll get there but I think we'll face selling pressure at regular points on the way up. Not that this matters to day traders.
Well I did think we were over-valued at 250p, but not by nearly three times - so I'd agree today's price make it a bargain. Maybe you are right about there being a big player influencing this dive, even if so I suspect the lack of news flow is having an impact. Since the big hurrah about the Vegas launch of a domestic machine in January there's been one small acquisition and some figures confirming we are still in the big spending phase of development. This is a bigger swing than I'd have expected but I'd think it's ready to start going up again very soon - there's just too much potential.
Within two months of me first buying this share we doubled from around 15p to around 30p. This investing game is a piece of cake I thought. So, based simply on hope on rather than detailed assessment of matters as prosaic as projected income, profitability etc, I'd like to see us return to that level by the time we start making money in 2020. Today's news giving us a foothold in the UK should help eh?
My favourite theory is that the Purp account is actually Freddie's alter-ego - his dark side pushed out by months and months of declining SP. Anyway what a very pleasant experience to see this going in the other direction with some gusto.
For those of us for whom this tech talk is a bit over our heads, the JK is now passing the Orkneys and is just offshore from the village of, erm, Twatt.
A landlubbers question from landlocked Leicestershire - will the Jumbo Kinetic go through the channel and up the East Coast? Or round Ireland to the West? Through the Irish Sea?
I don't understand - if you are a long term holder, then why are you so peeved about the short-term fluctuations caused by some of the shenanigans that always accompany fundraising? Were you maybe hoping to make a quick buck yourself by selling when we were readmitted? I think most long termers by definition are more concerned to see the company grow. Your comments about TC come across as ignorant, petulant and rude.
Even if you are not holding in ISA you can realise gains of �11,700 each year before being liable to CGT. For small time players like me that's plenty.